# Perioperative immune window

Source: https://onco.cc/terms/perioperative-immune-window/  
OnCo record `perioperative-immune-window` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Surgery and recovery can temporarily change immune activity. Studies of blood or laboratory markers differ from trials measuring recurrence, and a marker change alone does not show better cancer outcomes.

## Summary

Several things happen at once around an operation. Reviews describe a stress response in which injury and stress release catecholamines, prostaglandins and cortisol, and in which a short pro-inflammatory phase is followed by a prolonged anti-inflammatory phase; natural killer (NK) cells are severely affected in that period, and sympathetic stress factors, mediators including interleukin 6 and transforming growth factor beta, and myeloid-derived suppressor cells have been proposed as mediators (Horowitz and colleagues; Angka and colleagues). Wound healing adds repair signals, and anaesthesia and pain control add their own possible effects: the breast cancer anaesthesia trials were built on the premise that the surgical stress response, volatile anaesthetic and opioids impair host defence and that regional anaesthesia with propofol ameliorates all three. Most of this mechanistic evidence comes from blood measurements in patients and from mouse models, so whether the changes alter recurrence in people is a separate question that randomised trials answer best.

A real, short-lived shift in NK-cell function and suppressive signals is described by human blood studies and mouse work, which do not measure recurrence. Anaesthetic choice in breast cancer surgery was tested in two randomised trials. Sessler and colleagues analysed 2,108 women (13 hospitals, 8 countries) given regional anaesthesia with paravertebral blocks and propofol or general anaesthesia with sevoflurane and opioid analgesia: recurrence occurred in 102 of 1,043 (10%) and 111 of 1,065 (10%), hazard ratio 0.97 (95% CI 0.74 to 1.28), median follow-up 36 months; the trial stopped after a preplanned futility boundary was crossed, and persistent incisional pain did not differ. Enlund and colleagues (the Cancer and Anaesthesia study, designed to detect an advantage of at least five percentage points for propofol) recruited 1,764 women, of whom 1,670 remained for analysis, and found five-year survival of 773 of 841 (91.9%) with propofol and 764 of 829 (92.2%) with sevoflurane, hazard ratio 1.03 (95% CI 0.73 to 1.44). Neither trial detected an advantage in its specified clinical endpoint. Their confidence intervals do not prove that all anaesthetic approaches are equivalent; keep the agents, breast-cancer population, endpoint and follow-up attached.

Blocking the stress signals is a different question. In a randomised, placebo-controlled biomarker trial of 38 women with early breast cancer, 11 days of propranolol (a beta-blocker) with etodolac (a COX-2 inhibitor) from 5 days before surgery was well tolerated and changed tumour gene expression (less epithelial-to-mesenchymal transition, fewer tumour-infiltrating monocytes, more tumour-infiltrating B cells) and blood markers (smaller presurgical rises in interleukin 6 and C-reactive protein) (Shaashua and colleagues). Recurrence was not an endpoint, so this is a biomarker result and not fewer recurrences.

Timing of immunotherapy is another open question. In two mouse models of spontaneously metastatic breast cancer, immunotherapy given before removal of the primary tumour eradicated distant metastases more effectively than the same treatment given after, with sustained peripheral tumour-specific immune responses underpinning the outcome (Liu and colleagues). That supports testing the idea in people; it is not a human result. The KEYNOTE-522 regimen gives pembrolizumab with chemotherapy before surgery and alone after it to the same patients, so by design it cannot separate the benefit of the two phases (inference from the trial design).

## Fields

- Kind: Term
- Last checked: 2026-11-12
- Also known as: perioperative immunosuppression; surgical stress response; postoperative immunosuppression; anaesthesia and cancer recurrence

## Notes

- The window is a research question about transient changes around an operation, not evidence that avoiding or delaying surgery improves outcomes. Horowitz and colleagues proposed mechanisms by which perioperative stress could facilitate metastasis. The two breast-surgery anaesthesia trials did not detect the tested recurrence or survival advantage. The propranolol-etodolac study measured biomarkers and was not a test of reduced recurrence. Horowitz and colleagues frame the perioperative period in days to weeks; that review timeframe is not a universal measured duration of immune suppression or proof of one period of recurrence risk for every person.
- Keep the measurement level beside the claim. A blood measurement is not a tumour measurement: lower NK-cell function in blood after surgery does not show what immune cells do at a site of residual disease. A biomarker change is not fewer recurrences, as the propranolol and etodolac trial measured markers and not outcomes. An observational or laboratory suggestion is not a trial result, and the two breast cancer anaesthesia trials tested it directly.
- Worked example (inference). A reader sees that inhaled anaesthetics can suppress immune cells in laboratory studies and asks whether intravenous-only anaesthesia would lower breast cancer recurrence. The laboratory observation raised the idea; the two randomised trials in breast cancer surgery, each with more than 1,600 women analysed, found no difference in recurrence or survival between the anaesthetic strategies tested. Sessler and colleagues concluded that clinicians can use regional or general anaesthesia with respect to recurrence and persistent incisional pain.
- The reviewed perioperative mechanisms include repair-related growth signals, angiogenic changes and TGF-beta-associated regulation. Horowitz’s 2015 review discusses increased growth factors and altered proangiogenic and antiangiogenic signals after tissue injury; these are proposed routes to study, not a measured personal recurrence effect. Angka’s 2017 review describes postoperative myeloid suppressor cells, their recruitment of regulatory T cells and patient-blood-to-mouse experiments involving angiogenesis. Those model and blood observations do not directly measure immune control at every residual-disease site.

## Sources

- Horowitz et al., exploiting the critical perioperative period to improve long-term cancer outcomes (Nat Rev Clin Oncol 2015): https://pubmed.ncbi.nlm.nih.gov/25601442/
- Angka et al., dysfunctional natural killer cells in the aftermath of cancer surgery (Int J Mol Sci 2017): https://pubmed.ncbi.nlm.nih.gov/28817109/
- Sessler et al., recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial (Lancet 2019): https://pubmed.ncbi.nlm.nih.gov/31645288/
- Enlund et al., impact of general anaesthesia on breast cancer survival: a 5-year follow up of a pragmatic, randomised, controlled trial, the CAN-study (eClinicalMedicine 2023): https://pubmed.ncbi.nlm.nih.gov/37333664/
- Shaashua et al., perioperative COX-2 and beta-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase II randomized trial (Clin Cancer Res 2017): https://pubmed.ncbi.nlm.nih.gov/28490464/
- Liu et al., improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease (Cancer Discov 2016): https://pubmed.ncbi.nlm.nih.gov/27663893/
- Schmid et al., pembrolizumab for early triple-negative breast cancer (N Engl J Med 2020): https://pubmed.ncbi.nlm.nih.gov/32101663/

## Connected records

- terms: [Neoadjuvant / adjuvant / perioperative](https://onco.cc/terms/neoadjuvant-adjuvant/), [NK cell](https://onco.cc/terms/nk-cell/)
- trials: [KEYNOTE-522](https://onco.cc/trials/keynote-522/)
- ideas: [Cheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress](https://onco.cc/ideas/idea-bio2-perioperative-betablocker-nsaid/), [Perioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery](https://onco.cc/ideas/idea-reg-perioperative-propranolol-etodolac/)
- pathways: [NK-cell recognition: missing self & stress ligands](https://onco.cc/pathways/nk-cell-recognition/), [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)

---
JSON: https://onco.cc/api/v1/entities/perioperative-immune-window.json